发布求助
文献互助 智能选刊 最新文献

Personalized medicine最新文献

筛选
英文 中文
IL-6 gene polymorphism predicts PEGylated IFN-α treatment response in hepatitis B surface antigen-positive chronic hepatitis B patients. IL-6基因多态性预测乙型肝炎表面抗原阳性慢性乙型肝炎患者聚乙二醇化IFN-α治疗反应。
Personalized medicine Pub Date : 2023-11-01 DOI: 10.2217/pme-2023-0089
Xiaoqing Wang, Xiu Gu, Fengli Liu
{"title":"<i>IL-6</i> gene polymorphism predicts PEGylated IFN-α treatment response in hepatitis B surface antigen-positive chronic hepatitis B patients.","authors":"Xiaoqing Wang, Xiu Gu, Fengli Liu","doi":"10.2217/pme-2023-0089","DOIUrl":"10.2217/pme-2023-0089","url":null,"abstract":"<p><p><b>Background:</b> Genetic polymorphism can affect the response to antiviral therapy of chronic hepatitis B (CHB) patients. <b>Objective:</b> The study examined the genetic association of the <i>IL-6</i> rs1800796 polymorphism with PEGylated IFN-α (PegIFN-α) treatment response in hepatitis B surface antigen (HBsAg)-positive CHB patients. <b>Methods:</b> Direct sequencing was done for the genotyping of the rs1800796 polymorphism in the serum of CHB patients. <b>Results:</b> More patients with combined response (n = 95) carried <i>IL-6</i> rs1800796 GC genotypes, while CC genotype carriers possessed reduced HBeAg seroconversion rate and high values of hepatitis B virus DNA. Baseline HBsAg and HBeAg and <i>IL-6</i> rs1800796 CC genotype were independently related to PegIFN-α treatment response. <b>Conclusion:</b> Detection of the <i>IL-6</i> rs1800796 genotype in CHB patients may have potential guiding significance for PegIFN-α response.</p>","PeriodicalId":94167,"journal":{"name":"Personalized medicine","volume":" ","pages":"503-510"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71430631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
LncRNA polymorphisms and lung cancer risk. LncRNA多态性与癌症风险。
Personalized medicine Pub Date : 2023-11-01 Epub Date: 2023-11-02 DOI: 10.2217/pme-2023-0081
Esmat Abdi, Saeid Latifi-Navid, Alireza Panahi, Hamid Latifi-Navid
{"title":"LncRNA polymorphisms and lung cancer risk.","authors":"Esmat Abdi, Saeid Latifi-Navid, Alireza Panahi, Hamid Latifi-Navid","doi":"10.2217/pme-2023-0081","DOIUrl":"10.2217/pme-2023-0081","url":null,"abstract":"<p><p>Lung cancer (LC) imposes a significant burden, and is associated with high mortality and morbidity among malignant tumors. Aberrant expression of particular lncRNAs is closely linked to LC. LncRNA polymorphisms cause abnormal expression levels and/or structural dysfunction. They can affect the progression of cancer, survival, response to chemotherapy and recurrence rates in cancer patients. The present article provides a comprehensive overview of the effect of lncRNA genetic polymorphisms on LC. It is proposed that lncRNA-related variants can be used to predict cancer risk and therapeutic outcomes. More large-scale trials on diverse ethnic groups are required to validate the results, thus personalizing LC therapy based on lncRNA genotypes.</p>","PeriodicalId":94167,"journal":{"name":"Personalized medicine","volume":" ","pages":"511-522"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71430633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A real-world analysis of tyrosine receptor kinase inhibitor-related toxicities in cancer treatment. 癌症治疗中酪氨酸受体激酶抑制剂相关毒性的现实世界分析。
Personalized medicine Pub Date : 2023-11-01 DOI: 10.2217/pme-2023-0072
Wenjie Li, Keshan Wen, Weijie Zhu, Shangfei Luo
{"title":"A real-world analysis of tyrosine receptor kinase inhibitor-related toxicities in cancer treatment.","authors":"Wenjie Li, Keshan Wen, Weijie Zhu, Shangfei Luo","doi":"10.2217/pme-2023-0072","DOIUrl":"10.2217/pme-2023-0072","url":null,"abstract":"<p><p><b>Background:</b> This study analyzed real-world data from 2004 to 2023 to evaluate the toxicity profile of tyrosine receptor kinase (TRK) inhibitor therapy. <b>Method:</b> A retrospective analysis of US FDA Adverse Event Reporting System data was conducted to identify adverse events in patients receiving TRK inhibitor therapy. <b>Result:</b> Entrectinib demonstrated toxicities primarily in the cardiovascular and nervous systems, followed by the renal and urinary system. Common adverse effects included dizziness, renal impairment, constipation, heart failure and taste disorders. Larotrectinib induced adverse events mainly in the hepatobiliary and nervous systems, with peripheral neuropathy, myalgia, renal impairment and increased alanine aminotransferase commonly reported. <b>Conclusion:</b> Careful monitoring and supportive care strategies are essential for managing adverse events associated with TRK inhibitor therapy.</p>","PeriodicalId":94167,"journal":{"name":"Personalized medicine","volume":" ","pages":"485-491"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71430632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Low rate of complications in nipple-sparing mastectomy for patients with BRCA1 and BRCA2 mutation. BRCA1和BRCA2突变患者保留乳头乳房切除术并发症发生率低。
Personalized medicine Pub Date : 2023-11-01 DOI: 10.2217/pme-2023-0084
Antônio Luiz Frasson, Ana Beatriz Falcone, Fernanda Barbosa, Alessandra Borba Anton de Souza, Carolina Malhone, Isabela Miranda, Betina Vollbrecht, Monica Adriana Rodriguez Martinez Frasson, Luiza Kobe, Martina Lichtenfels
{"title":"Low rate of complications in nipple-sparing mastectomy for patients with <i>BRCA1</i> and <i>BRCA2</i> mutation.","authors":"Antônio Luiz Frasson, Ana Beatriz Falcone, Fernanda Barbosa, Alessandra Borba Anton de Souza, Carolina Malhone, Isabela Miranda, Betina Vollbrecht, Monica Adriana Rodriguez Martinez Frasson, Luiza Kobe, Martina Lichtenfels","doi":"10.2217/pme-2023-0084","DOIUrl":"10.2217/pme-2023-0084","url":null,"abstract":"<p><p><b>Background:</b> To describe the indications and outcomes of <i>BRCA</i> mutation carriers undergoing nipple-sparing mastectomy (NSM). <b>Methods:</b> In this retrospective study, 76 <i>BRCA</i> mutation carriers with no cancer who opted to undergo risk reduction NSM or diagnosed with breast cancer (BC) who opted to undergo therapeutic NSM were included. <b>Results:</b> Indications for NSM: cancer treatment (n = 33), bilateral risk reduction (n = 39) and contralateral prophylactic NSM (n = 4). In a mean follow-up of 45 months (median: 30 months), one patient (2.5%) undergoing risk-reducing NSM developed a new BC. One (3%) local, one (3%) ipsilateral axillary and one (3%) distant recurrence were observed in BC patients. No partial or total nipple necrosis occurred. <b>Conclusion:</b> NSM is safe for reducing the risk of BC development in <i>BRCA</i> mutation carriers and for treating cancer.</p>","PeriodicalId":94167,"journal":{"name":"Personalized medicine","volume":" ","pages":"493-501"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71430634","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Personalized medicine, the inevitable future of cancer immunotherapy. 个性化医疗，癌症免疫治疗的必然未来。
Personalized medicine Pub Date : 2023-09-01 Epub Date: 2023-10-06 DOI: 10.2217/pme-2023-0083
Mohsen Basiri
{"title":"Personalized medicine, the inevitable future of cancer immunotherapy.","authors":"Mohsen Basiri","doi":"10.2217/pme-2023-0083","DOIUrl":"10.2217/pme-2023-0083","url":null,"abstract":"","PeriodicalId":94167,"journal":{"name":"Personalized medicine","volume":" ","pages":"413-416"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41169949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of CYP2C9*2 and *3 polymorphisms on valproate-associated adverse drug reactions in individuals living with epilepsy: a case-control study. CYP2C9*2和*3多态性对癫痫患者丙戊酸钠相关药物不良反应的影响：一项病例对照研究。
Personalized medicine Pub Date : 2023-09-01 Epub Date: 2023-10-09 DOI: 10.2217/pme-2023-0033
Kirubakaran Ramakrishnan, Ramasamy Kesavan, Shravan Venkatraman, Sunil K Narayan, Ramachandran Ramesh Kumar, Deepak Shewade
{"title":"Impact of <i>CYP2C9*2</i> and <i>*3</i> polymorphisms on valproate-associated adverse drug reactions in individuals living with epilepsy: a case-control study.","authors":"Kirubakaran Ramakrishnan,&nbsp;Ramasamy Kesavan,&nbsp;Shravan Venkatraman,&nbsp;Sunil K Narayan,&nbsp;Ramachandran Ramesh Kumar,&nbsp;Deepak Shewade","doi":"10.2217/pme-2023-0033","DOIUrl":"10.2217/pme-2023-0033","url":null,"abstract":"<p><p>Epilepsy is characterized by repeated seizure activity. Valproate, a commonly used antiepileptic drug, shows large inter-individual variation in plasma valproic levels and causes many adverse drug reactions. <b>Aim:</b> To find the influence of <i>CYP2C9*2</i> and <i>*3</i> polymorphisms on valproate-associated adverse drug reactions and plasma valproic acid levels in people with epilepsy. <b>Methods:</b> We recruited 158 people with epilepsy (79 cases and 79 controls) from an epilepsy clinic. Steady-state plasma valproic acid levels were measured using liquid chromatography-mass spectrometry and genotyping of <i>CYP2C9</i> variants was carried out with helps of RT-PCR. <b>Results:</b> The presence of a mutant heterozygous genotype showed an odds ratio (OR) of 2.82 (95% CI: 1.10-7.24) and the adjusted OR was 5.39 (95% CI: 1.69-17.16). There was no significant difference in steady-state plasma valproate concentration between genotypes. <b>Conclusion:</b> The presence of a mutant heterozygous <i>CYP2C9</i> genotype possesses five-times the risk of developing adverse drug reactions to valproate in people with epilepsy.</p>","PeriodicalId":94167,"journal":{"name":"Personalized medicine","volume":" ","pages":"417-424"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41143759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Complete mesogastric excision for gastric cancer: is it the future of gastric cancer surgery? 癌症完全胃中切除术：这是癌症手术的未来吗？
Personalized medicine Pub Date : 2023-09-01 Epub Date: 2023-10-09 DOI: 10.2217/pme-2023-0028
Georgios D Lianos, Christina D Bali, Konstantinos Vlachos, Panagiota Drosou, Stefano Rausei, Michail Mitsis, Dimitrios Schizas
{"title":"Complete mesogastric excision for gastric cancer: is it the future of gastric cancer surgery?","authors":"Georgios D Lianos,&nbsp;Christina D Bali,&nbsp;Konstantinos Vlachos,&nbsp;Panagiota Drosou,&nbsp;Stefano Rausei,&nbsp;Michail Mitsis,&nbsp;Dimitrios Schizas","doi":"10.2217/pme-2023-0028","DOIUrl":"10.2217/pme-2023-0028","url":null,"abstract":"<p><p>Gastric cancer remains undoubtedly one of the most common and deadly cancers worldwide. The global incidence shows wide geographic variation with a high prevalence in Asia. Besides that, there are evident differences in epidemiology, histopathology, tumor location, diagnosis and treatment strategy between east and west countries. Gastric cancer represents an aggressive disease, with many factors influencing its development and also recurrence after surgical resection. New knowledge of disease spread and new routes of metastases are now emerging and the 'novel' concept of complete mesogastric excision for gastric cancer is under consideration and debate. This article aims to analyze and highlight this new concept after a careful literature review, offering also a view toward the future.</p>","PeriodicalId":94167,"journal":{"name":"Personalized medicine","volume":" ","pages":"461-466"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41176534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Maternal and placental ANRIL polymorphisms and preeclampsia susceptibility. 母体和胎盘ANRIL多态性与先兆子痫易感性。
Personalized medicine Pub Date : 2023-09-01 Epub Date: 2023-10-18 DOI: 10.2217/pme-2023-0073
Mina Asadi-Tarani, Mohsen Saravani, Marzieh Ghasemi, Mahnaz Rezaei, Saeedeh Salimi
{"title":"Maternal and placental <i>ANRIL</i> polymorphisms and preeclampsia susceptibility.","authors":"Mina Asadi-Tarani,&nbsp;Mohsen Saravani,&nbsp;Marzieh Ghasemi,&nbsp;Mahnaz Rezaei,&nbsp;Saeedeh Salimi","doi":"10.2217/pme-2023-0073","DOIUrl":"10.2217/pme-2023-0073","url":null,"abstract":"<p><p><b>Aim:</b> The possible effects of maternal and placental <i>ANRIL</i> polymorphisms on preeclampsia were examined. <b>Methods:</b> The maternal blood of 315 preeclamptic and 317 control women and the placentas of 103 preeclamptic and 133 control women were enrolled in the study. <i>ANRIL</i> polymorphisms were genotyped using a PCR-RFLP method. <b>Results:</b> The maternal <i>ANRIL</i> rs1333048C variant showed a relationship with a lower risk of preeclampsia in codominant and dominant models. The maternal <i>ANRIL</i> rs4977574G variant had a relationship with a lower risk of preeclampsia in codominant and recessive models. There was an association between the placental rs1333048C variant and a lower risk of preeclampsia in codominant and dominant models. <b>Conclusion:</b> Maternal <i>ANRIL</i> rs1333048C and rs4977574G variants and placental rs1333048 variant showed a relationship with a lower risk of preeclampsia.</p>","PeriodicalId":94167,"journal":{"name":"Personalized medicine","volume":"20 5","pages":"445-452"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41242784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cloud-based digital healthcare development for precision medical hospital information system. 基于云的数字医疗开发，用于精准医疗的医院信息系统。
Personalized medicine Pub Date : 2023-09-01 Epub Date: 2023-10-09 DOI: 10.2217/pme-2023-0074
SeJun Oh, Hyung Joon Joo, Jang Wook Sohn, Sangsoo Park, Jin Su Jang, Jiwon Seong, Kwang Jin Park, Sang Heon Lee
{"title":"Cloud-based digital healthcare development for precision medical hospital information system.","authors":"SeJun Oh,&nbsp;Hyung Joon Joo,&nbsp;Jang Wook Sohn,&nbsp;Sangsoo Park,&nbsp;Jin Su Jang,&nbsp;Jiwon Seong,&nbsp;Kwang Jin Park,&nbsp;Sang Heon Lee","doi":"10.2217/pme-2023-0074","DOIUrl":"10.2217/pme-2023-0074","url":null,"abstract":"<p><p><b>Aim:</b> This study aims to develop a cloud-based digital healthcare system for precision medical hospital information systems (P-HIS). <b>Methods:</b> In 2020, international standardization of P-HIS clinical terms and codes was performed. In 2021, South Korea's first tertiary hospital cloud was established and implemented successfully. <b>Results:</b> P-HIS was applied at Korea's first tertiary general hospital. Common data model-compatible precision medicine/medical service solutions were developed for medical support. Ultrahigh-quality medical data for precision medicine were acquired and built using big data. Joint global commercialization and dissemination/spreading were achieved using the P-HIS consortium and global common data model-based observational medical outcome partnership network. <b>Conclusion:</b> To provide personalized precision medical services in the future, establishing and using big medical data is essential.</p>","PeriodicalId":94167,"journal":{"name":"Personalized medicine","volume":" ","pages":"435-444"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41173497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost-effectiveness of alternative NTRK testing strategies in cancer patients followed by histology-independent therapy with entrectinib: an analysis of three European countries. 癌症患者替代NTRK检测策略的成本-效果：对三个欧洲国家的分析。
Personalized medicine Pub Date : 2023-07-01 Epub Date: 2023-09-25 DOI: 10.2217/pme-2022-0070
Heleen Vellekoop, Simone Huygens, Matthijs Versteegh, László Szilberhorn, Tamás Zelei, Balázs Nagy, Rositsa Koleva-Kolarova, Sarah Wordsworth, Maureen Rutten-van Mölken
{"title":"Cost-effectiveness of alternative <i>NTRK</i> testing strategies in cancer patients followed by histology-independent therapy with entrectinib: an analysis of three European countries.","authors":"Heleen Vellekoop,&nbsp;Simone Huygens,&nbsp;Matthijs Versteegh,&nbsp;László Szilberhorn,&nbsp;Tamás Zelei,&nbsp;Balázs Nagy,&nbsp;Rositsa Koleva-Kolarova,&nbsp;Sarah Wordsworth,&nbsp;Maureen Rutten-van Mölken","doi":"10.2217/pme-2022-0070","DOIUrl":"10.2217/pme-2022-0070","url":null,"abstract":"<p><p><b>Aim:</b> To explore variations in the cost-effectiveness of entrectinib across different testing strategies and settings. <b>Methods:</b> Four testing strategies where adult cancer patients received entrectinib if they tested positive for <i>NTRK</i> gene fusions compared with 'no testing' and standard of care (SoC) for all patients were evaluated. <b>Results:</b> Immunohistochemistry for all patients followed by RNA-based next-generation sequencing after a positive result was the optimal strategy in all included countries. However, the incremental net monetary benefit compared with SoC was negative in all countries, ranging between international euros (int€) -206 and -404. In a subgroup analysis with only <i>NTRK</i>-positive patients, the incremental net monetary benefit was int€ 8405 in England, int€ -53,088 in Hungary and int€ 54,372 in The Netherlands. <b>Conclusion:</b> Using the cost-effectiveness thresholds recommended by national guidelines, none of the testing strategies were cost-effective compared with no testing. The implementation of entrectinib is unlikely to become cost-effective in Hungary, due to the large cost difference between the entrectinib and SoC arms, while there might be more potential in England and The Netherlands.</p>","PeriodicalId":94167,"journal":{"name":"Personalized medicine","volume":"20 4","pages":"321-338"},"PeriodicalIF":0.0,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41173534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信